UNITY Biotechnology Inc
NASDAQ:UBX
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
UNITY Biotechnology Inc
NASDAQ:UBX
|
US |
|
D
|
Dongyue Group Ltd
HKEX:189
|
CN |
|
Pilbara Minerals Ltd
ASX:PLS
|
AU |
|
Agnico Eagle Mines Ltd
TSX:AEM
|
CA |
|
Sichuan New Energy Power Co Ltd
SZSE:000155
|
CN |
|
Lutian Machinery Co Ltd
SSE:605259
|
CN |
|
Shenzhen Chuangyitong Technology Co Ltd
SZSE:300991
|
CN |
|
Hillstone Networks Co Ltd
SSE:688030
|
CN |
|
Lynas Rare Earths Ltd
XMUN:LYI
|
AU |
|
Sidus Space Inc
NASDAQ:SIDU
|
US |
|
S
|
Shenzhen Dynanonic Co Ltd
SZSE:300769
|
CN |
|
EchoIQ Ltd
ASX:EIQ
|
AU |
|
Distribusi Voucher Nusantara Tbk PT
IDX:DIVA
|
ID |
|
Natural Resource Partners LP
NYSE:NRP
|
US |
|
Spring Valley Acquisition Corp II
NASDAQ:SVII
|
US |
|
Shanghai Zhangjiang Hi-Tech Park Development Co Ltd
SSE:600895
|
CN |
|
Connected IO Ltd
ASX:CIO
|
US |
|
Fukuoka Financial Group Inc
OTC:FKKFY
|
JP |
|
Luoniushan Co Ltd
SZSE:000735
|
CN |
|
Jiangsu Flag Chemical Industry Co Ltd
SZSE:300575
|
CN |
|
C
|
Chongqing Changjiang River Moulding Material Group Co Ltd
SZSE:001296
|
CN |
|
T
|
Top Glove Corporation Bhd
KLSE:TOPGLOV
|
MY |
|
F
|
Farsoon Technologies Co Ltd
SSE:688433
|
CN |
|
Brilliance Technology Co Ltd
SZSE:300542
|
CN |
UNITY Biotechnology Inc
Unity Biotechnology, Inc. operates as a biotechnology company. The company is headquartered in Brisbane California, California and currently employs 65 full-time employees. The company went IPO on 2018-05-03. The firm is engaged in developing a portfolio of programs targeting specific biological mechanisms implicated in diseases of aging. The firm is focused on creating senolytic medicines to selectively eliminate senescent cells and thereby treat diseases of aging, such as ophthalmologic diseases, with the opportunity to explore neurology and other therapeutic areas. The firm's product includes UBX1325, UBX2089 and UBX2050. UBX1325 is an advanced lead drug candidate for age-related diseases of the eye, including diabetic macular edema (DME), age-related macular degeneration (AMD), and diabetic retinopathy (DR). UBX2089, an α-Klotho hormone drug candidate, is a circulating hormone primarily produced in the kidneys and choroid plexus of the brain, which is being researched for multiple neurology indications. UBX2050 is investigating fully human anti-Tie2 agonist monoclonal antibody.
Unity Biotechnology, Inc. operates as a biotechnology company. The company is headquartered in Brisbane California, California and currently employs 65 full-time employees. The company went IPO on 2018-05-03. The firm is engaged in developing a portfolio of programs targeting specific biological mechanisms implicated in diseases of aging. The firm is focused on creating senolytic medicines to selectively eliminate senescent cells and thereby treat diseases of aging, such as ophthalmologic diseases, with the opportunity to explore neurology and other therapeutic areas. The firm's product includes UBX1325, UBX2089 and UBX2050. UBX1325 is an advanced lead drug candidate for age-related diseases of the eye, including diabetic macular edema (DME), age-related macular degeneration (AMD), and diabetic retinopathy (DR). UBX2089, an α-Klotho hormone drug candidate, is a circulating hormone primarily produced in the kidneys and choroid plexus of the brain, which is being researched for multiple neurology indications. UBX2050 is investigating fully human anti-Tie2 agonist monoclonal antibody.
